• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales.

作者信息

Bail Larissa, Ito Carmen Antonia Sanches, Arend Lavinia Nery Villa Stangler, Nogueira Keite da Silva, Tuon Felipe Francisco

机构信息

Division of Microbiology, Universidade Estadual de Ponta Grossa do Paraná; Laboratory of Emerging Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil.

Laboratory of Emerging Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil; Laboratório Central do Estado do Paraná - LACEN.

出版信息

Diagn Microbiol Infect Dis. 2022 Jan;102(1):115568. doi: 10.1016/j.diagmicrobio.2021.115568. Epub 2021 Oct 8.

DOI:10.1016/j.diagmicrobio.2021.115568
PMID:34749296
Abstract
摘要

相似文献

1
Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales.亚胺培南-瑞来巴坦和头孢洛扎-他唑巴坦对耐碳青霉烯类铜绿假单胞菌和产KPC肠杆菌科细菌的活性。
Diagn Microbiol Infect Dis. 2022 Jan;102(1):115568. doi: 10.1016/j.diagmicrobio.2021.115568. Epub 2021 Oct 8.
2
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021.在希腊和意大利收集的肠杆菌科和铜绿假单胞菌临床分离株中头孢洛扎/他唑巴坦和亚胺培南/雷利巴坦的活性-SMART 2017-2021。
Eur J Clin Microbiol Infect Dis. 2024 Jul;43(7):1343-1348. doi: 10.1007/s10096-024-04756-4. Epub 2024 May 22.
3
Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli.亚胺培南-雷巴他定和头孢他啶-他唑巴坦对耐药革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00533-18. Print 2018 Aug.
4
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.亚胺培南/瑞来巴坦和头孢洛扎/他唑巴坦对具有难治性耐药和多重耐药表型的革兰氏阴性杆菌临床分离株的体外活性——美国2015 - 2017年抗菌药物耐药趋势监测研究
Clin Infect Dis. 2021 Jun 15;72(12):2112-2120. doi: 10.1093/cid/ciaa381.
5
Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.头孢他洛滨-他唑巴坦对产碳青霉烯酶非产碳青霉烯酶耐药铜绿假单胞菌的活性及相关耐药机制。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01970-17. Print 2018 Jan.
6
In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance.在日本抗菌药物耐药性细菌监测中收集的产碳青霉烯酶和对美罗培南不敏感的革兰氏阴性菌的体外活性研究。
J Glob Antimicrob Resist. 2024 Sep;38:12-20. doi: 10.1016/j.jgar.2024.05.009. Epub 2024 May 22.
7
Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa.产 KPC 肺炎克雷伯菌和耐碳青霉烯类铜绿假单胞菌中亚胺培南/雷巴他定与其他药物的活性比较。
Eur J Clin Microbiol Infect Dis. 2024 Mar;43(3):445-457. doi: 10.1007/s10096-023-04735-1. Epub 2023 Dec 29.
8
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.德国碳青霉烯类耐药铜绿假单胞菌的传播及其对头孢他啶-他唑巴坦的药敏情况。
Int J Antimicrob Agents. 2020 Jun;55(6):105959. doi: 10.1016/j.ijantimicag.2020.105959. Epub 2020 Apr 20.
9
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in .产超广谱β-内酰胺酶 GES-6 的获得导致. 对头孢洛扎他巴坦联合制剂的耐药性
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01809-18. Print 2019 Jan.
10
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.头孢地尔肟、亚胺培南/雷巴他定、头孢吡肟/他唑巴坦和头孢吡肟/齐多夫定对头孢他啶/他唑巴坦和头孢噻肟/阿维巴坦耐药铜绿假单胞菌的活性。
J Antimicrob Chemother. 2022 Sep 30;77(10):2809-2815. doi: 10.1093/jac/dkac241.

引用本文的文献

1
Economic Impact in the Treatment of Coagulase-Negative Staphylococci Blood Cultures Contamination in a Middle-Income Country.中等收入国家凝固酶阴性葡萄球菌血培养污染治疗中的经济影响
Rev Soc Bras Med Trop. 2025 Aug 8;58:e00942025. doi: 10.1590/0037-8682-0094-2025. eCollection 2025.
2
Difficult-to-Treat Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal.重症患者难治性感染：综述与治疗建议
Antibiotics (Basel). 2025 Feb 11;14(2):178. doi: 10.3390/antibiotics14020178.
3
Combined therapeutic option for NDM-producing Serratia Marcescens - an in vitro study from clinical samples.
产NDM的粘质沙雷氏菌的联合治疗方案——一项来自临床样本的体外研究
Braz J Infect Dis. 2025 Jan-Feb;29(1):104481. doi: 10.1016/j.bjid.2024.104481. Epub 2024 Nov 26.
4
The pattern of antibiotic resistance and distribution of the biofilm-producing () isolated from infectious hospital departments.从感染性医院科室分离出的产生物膜（）的抗生素耐药模式及分布情况。 （注：原文括号处内容缺失）
SAGE Open Med. 2024 Nov 15;12:20503121241298826. doi: 10.1177/20503121241298826. eCollection 2024.
5
Molecular epidemiology and carbapenem resistance mechanisms of isolated from a hospital in Fujian, China.从中国福建一家医院分离出的分子流行病学及碳青霉烯类耐药机制
Front Microbiol. 2024 Sep 5;15:1431154. doi: 10.3389/fmicb.2024.1431154. eCollection 2024.
6
Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis.亚胺培南/瑞来巴坦对革兰氏阴性杆菌的全球耐药性：系统评价和荟萃分析
Curr Ther Res Clin Exp. 2023 Oct 28;100:100723. doi: 10.1016/j.curtheres.2023.100723. eCollection 2024.
7
Severe infections caused by difficult-to-treat Gram-negative bacteria.严重的感染由难以治疗的革兰氏阴性菌引起。
Curr Opin Crit Care. 2023 Oct 1;29(5):438-445. doi: 10.1097/MCC.0000000000001074. Epub 2023 Jul 31.
8
Susceptibility profile and β-lactamase content of global isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam-SMART 2016-21.2016 - 2021年全球对头孢洛扎/他唑巴坦和/或亚胺培南/瑞来巴坦耐药菌株的药敏谱及β-内酰胺酶含量 - SMART研究
JAC Antimicrob Resist. 2023 Jun 28;5(3):dlad080. doi: 10.1093/jacamr/dlad080. eCollection 2023 Jun.
9
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study.碳青霉烯类耐药铜绿假单胞菌和相关碳青霉烯酶（POP）的全球流行病学和临床结局：一项前瞻性队列研究。
Lancet Microbe. 2023 Mar;4(3):e159-e170. doi: 10.1016/S2666-5247(22)00329-9. Epub 2023 Feb 9.
10
New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.新视角下的抗菌药物：亚胺培南-雷巴他定。
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0025622. doi: 10.1128/aac.00256-22. Epub 2022 Jun 21.